Company Profile

Dynamis Therapeutics Inc
Profile last edited on: 6/5/19      CAGE: 477V3      UEI:

Business Identifier: Therapeutic pharmaceuticals chronic inflammatory disease
Year Founded
1997
First Award
2000
Latest Award
2010
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

261 Old York Road Suite 427
Jenkintown, PA 19046
   (215) 376-5290
   info@meg21.com
   www.dynamis-therapeutics.com
Location: Single
Congr. District: 04
County: Montgomery

Public Profile

Originally addressing complications of diabetes and aging, engaging technology licensed from Fox Chase Cancer Center and involving several personnel from that establishment, Dynamis Therapeutics, Inc. organzied around developing new drugs to treat chronic inflammatory disease. The underlying concept was that of lowering the levels of 3-deoxyglucosone. Products include DYN 15, a drug candidate that prevents the formation of 3DG, a highly reactive sugar, as well as lowers the levels of several key cytokines that are stimulated in chronic inflammations. The company's products also include an enzymatic pathway that causes chronic inflammation; and MEG 21, an anti-aging treatment product for face treatment, hand treatment, eye treatment, anti-oxidant boosting, and redness relief. The firm's proprietary drug candidates inhibit a novel enzymatic pathway that causes the formation of a highly reactive sugar, 3-deoxyglucosone, that stimulates the production of Advanced Glycation End Products (AGEs), oxidative stress and a cascade of inflammatory cytokines.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $257,579
Project Title: Discovery Of Fn3k Inhibitors To Treat Diabetic Complications
2005 2 NIH $1,132,651
Project Title: High Throughput Screen for Amadorase Inhibitors
2003 1 NIH $133,750
Project Title: New Inhibitors for Diabetic Retinopathy
2002 1 NIH $100,000
Project Title: Cloning Amadorase: A Therapeutic Target for Nephropathy
2000 1 NIH $100,000
Project Title: New Inhibitors For Diabetic Nephropathy

Key People / Management

  Annette M Tobia -- Founder, CEO, and President

  Erika Geimonen -- Vice President of Business Development

  Frank Kappler -- Scientific Founder, Chief Scientific Officer and Vice President of Research

  Alice Marcy

  William C Randall

  Michael L Schwartz

  Bangying Su -- Scientific Founder and Director of Chemistry

Company News

There are no news available.